Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IKZF1
REST API REST API
Homo sapiens
IKZF1 is differentially expressed in 295 experiments: 124 organism parts: bone marrow, thymus, ... (122 more);, 289 disease states: normal, prostate carcinoma, ... (287 more);, 107 cell types 469 cell lines 40 compound treatments and 82 other conditions.
Synonyms LyF-1, Hs.54452, hIk-1, IKAROS, ZNFN1A1
Orthologs ikzf1 (Danio rerio)   IKZF1 (Gallus gallus)   Ikzf1 (Mus musculus)   ENSCING00000006863 (Ciona intestinalis)   IKZF1 (Bos taurus)   Ikzf1 (Rattus norvegicus)   ikzf1 (Xenopus laevis)   IKZF1 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytoplasm, intracellular, metal ion binding, nucleic acid binding, positive regulation of multicellular organism growth, centromeric heterochromatin, sequence-specific DNA binding, hemopoiesis, cell cycle, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, nucleus, mesoderm development, protein heterodimerization activity, chromatin modification, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, zinc ion binding, B cell differentiation, Peyer's patch development, positive regulation of neutrophil differentiation, forebrain development, natural killer cell differentiation, lymph node development, positive regulation of NK T cell differentiation, retina development in camera-type eye, thymus development, T cell differentiation, gland development, sequence-specific DNA binding transcription factor activity
UniProt Accession Q13422, Q69BM4, Q3T907, C9JTB0
Search EB-eye ENSG00000185811
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7224, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
Jurkat
3
E-GEOD-1880, E-MTAB-62, E-MEXP-2197
AGS
2
E-MTAB-37, E-GEOD-15460
BT-474
2
E-GEOD-5823, E-GEOD-3529
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
463 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (50 experiments)

Factor Value U/D Experiments
stromal cell
3
E-GEOD-1460, E-MEXP-2034, E-MEXP-1121
CD8+ T cell
1
3
E-AFMX-5, E-TABM-145, E-GEOD-19069, E-GEOD-6740
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-26672
macrophage
2
E-GEOD-3982, E-GEOD-22373
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-GEOD-16363, E-MTAB-62, ... (70 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
4
E-MTAB-37, E-MTAB-62, E-GEOD-5550, E-GEOD-96
glioblastoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-4412
prostate carcinoma
2
4
E-MTAB-62, E-GEOD-96, E-MTAB-37, E-MEXP-2034, E-GEOD-3868, ... (6 experiments)
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
retinoblastoma
2
E-MTAB-37, E-GEOD-96
prostate cancer
2
E-MTAB-62, E-GEOD-6919
283 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-697, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (23 experiments)

Factor Value U/D Experiments
none
4
7
E-TABM-782, E-GEOD-5824, E-MEXP-1958, E-TABM-868, E-GEOD-412, ... (11 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
no estradiol
1
E-GEOD-20081
anti-CD3 + anti-CD28
1
E-GEOD-7307
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-19246, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-12773, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-3720, ... (42 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-17636, E-GEOD-7114, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-22541, E-GEOD-7307 ... (5 experiments)

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (7 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Processing time: 0.572 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM